(Q40064095)

17 September 2017

title

Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction (English)

1 reference

17 September 2017

1 reference

Hovav Nechushtan

1

1 reference

17 September 2017

Dien Pham

2

1 reference

17 September 2017

Yu Zhang

3

1 reference

17 September 2017

Daniel Morgensztern

4

1 reference

17 September 2017

Kyung H Yi

5

1 reference

17 September 2017

Seung-Uon Shin

6

1 reference

17 September 2017

Howard J Federoff

7

1 reference

17 September 2017

William J Bowers

8

1 reference

17 September 2017

Khaled A Tolba

9

1 reference

17 September 2017

Joseph D Rosenblatt

10

1 reference

17 September 2017

publication date

19 October 2007

1 reference

Cancer Immunology, Immunotherapy

17 September 2017

published in

1 reference

17 September 2017

volume

57

1 reference

17 September 2017

issue

5

1 reference

17 September 2017

page(s)

663-675

1 reference

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.663

Guidelines for the management of rheumatoid arthritis: 2002 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.663

Interleukin-6: a new therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.663

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.663

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.663

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.663

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.663

Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.663

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.663

Interleukin-6 and the acute phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.663

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.663

Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.663

IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.663

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.663

21 January 2018

Identifiers

DOI

10.2217/14750708.5.5.663

1 reference

17 September 2017

1 reference